Analysts have lifted their Fair Value estimate for Quest Diagnostics from $223.44 to $239.38 following the company's second-quarter earnings beat and raised full-year guidance. The adjustment reflects updated models incorporating a revenue beat of 2% to $3.04 billion and an earnings per share beat of $0.30 versus Street expectations, along with higher revenue and earnings guidance. Bullish firms including BofA, Mizuho, Jefferies, and Barclays raised price targets into a $245 to $265 range, citing strong organic growth and sustained momentum, while UBS lifted its target to $232 but maintained a Neutral rating, flagging softer margins. Key changes in the Fair Value model include a slight decrease in revenue growth from 4.88% to 4.74%, an increase in profit margin from 10.67% to 11.01%, and a lower forward P/E from 21.17x to 20.92x.
Quest Diagnostics IncorporatedQ2 earnings beat and raised full-year guidance led to increased fair value estimate and price target upgrades from analysts.